Copeland Capital Management’s Pfizer PFE Stock Holding History

Copeland Capital Management’s Portfolio PFE Stock Details PFE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$36K	Sell	1,494 -3,489	-70%	-$91.3K	﹤0.01%	225
2026 Q1	$140K	Hold	4,983	–	–	﹤0.01%	165
2025 Q4	$124K	Hold	4,983	–	–	﹤0.01%	167
2025 Q3	$127K	Hold	4,983	–	–	﹤0.01%	163
2025 Q2	$121K	Hold	4,983	–	–	﹤0.01%	156
2025 Q1	$126K	Hold	4,983	–	–	﹤0.01%	153
2024 Q4	$132K	Hold	4,983	–	–	﹤0.01%	154
2024 Q3	$144K	Buy	+4,983	New	+$145K	﹤0.01%	147
2024 Q2	–	Sell	-4,983	Closed	-$138K	–	217
2024 Q1	$138K	Hold	4,983	–	–	﹤0.01%	145
2023 Q4	$143K	Hold	4,983	–	–	﹤0.01%	136
2023 Q3	$165K	Hold	4,983	–	–	﹤0.01%	139
2023 Q2	$183K	Hold	4,983	–	–	﹤0.01%	140
2023 Q1	$203K	Hold	4,983	–	–	﹤0.01%	139
2022 Q4	$255K	Hold	4,983	–	–	0.01%	137
2022 Q3	$218K	Sell	4,983 -335	-6%	-$16.3K	0.01%	138
2022 Q2	$279K	Hold	5,318	–	–	0.01%	134
2022 Q1	$275K	Hold	5,318	–	–	0.01%	134
2021 Q4	$314K	Hold	5,318	–	–	0.01%	132
2021 Q3	$229K	Hold	5,318	–	–	0.01%	137
2021 Q2	$208K	Hold	5,318	–	–	0.01%	140
2021 Q1	$193K	Hold	5,318	–	–	0.01%	141
2020 Q4	$196K	Sell	5,318 -287	-5%	-$10.5K	0.01%	137
2020 Q3	$195K	Hold	5,605	–	–	0.01%	128
2020 Q2	$174K	Hold	5,605	–	–	0.01%	128
2020 Q1	$174K	Hold	5,605	–	–	0.01%	127
2019 Q4	$208K	Hold	5,605	–	–	0.01%	132
2019 Q3	$191K	Hold	5,605	–	–	0.01%	132
2019 Q2	$230K	Hold	5,605	–	–	0.01%	125
2019 Q1	$226K	Sell	5,605 -2,718	-33%	-$109K	0.01%	127
2018 Q4	$345K	Sell	8,323 -45	-0.5%	-$1.87K	0.02%	123
2018 Q3	$350K	Hold	8,368	–	–	0.02%	138
2018 Q2	$288K	Hold	8,368	–	–	0.02%	132
2018 Q1	$282K	Hold	8,368	–	–	0.02%	128
2017 Q4	$288K	Buy	8,368 +45	+0.5%	+$1.53K	0.02%	137
2017 Q3	$282K	Hold	8,323	–	–	0.02%	131
2017 Q2	$265K	Sell	8,323 -385	-4%	-$12.1K	0.02%	126
2017 Q1	$285K	Hold	8,708	–	–	0.02%	127
2016 Q4	$268K	Hold	8,708	–	–	0.02%	137
2016 Q3	$280K	Hold	8,708	–	–	0.02%	164
2016 Q2	$291K	Hold	8,708	–	–	0.02%	150
2016 Q1	$245K	Hold	8,708	–	–	0.02%	152
2015 Q4	$267K	Hold	8,708	–	–	0.02%	168
2015 Q3	$260K	Buy	8,708 +353	+4%	+$11.3K	0.02%	153
2015 Q2	$266K	Buy	8,355 +385	+5%	+$12.5K	0.01%	182
2015 Q1	$263K	Hold	7,970	–	–	0.02%	186
2014 Q4	$236K	Sell	7,970 -2,719	-25%	-$78K	0.02%	161
2014 Q3	$300K	Hold	10,689	–	–	0.03%	139
2014 Q2	$301K	Hold	10,689	–	–	0.03%	134
2014 Q1	$326K	Hold	10,689	–	–	0.04%	127
2013 Q4	$311K	Hold	10,689	–	–	0.04%	104
2013 Q3	$291K	Buy	10,689 +2,719	+34%	+$74K	0.05%	91
2013 Q2	$212K	Buy	+7,970	New	+$220K	0.04%	93

Other funds holding PFE

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

Copeland Capital Management's PFE Position: Q2 2026 in Review

Copeland Capital Management reduced its Pfizer (PFE) stake by 70% in Q2 2026, selling an estimated $91.3K and leaving 1,494 shares worth $36K. The position accounts for ﹤0.01% of the portfolio, ranked #225.

Copeland Capital Management first reported a position in PFE in Q2 2013 and has held it in 52 quarters since. The position peaked at $350K in Q3 2018. 2,818 funds tracked by Wall St. Rank hold PFE as of Q2 2026.

Copeland Capital Management held 1,494 shares of Pfizer worth $36K as of Q2 2026.
Copeland Capital Management sold 3,489 Pfizer shares in Q2 2026, an estimated $91.3K.
Pfizer made up ﹤0.01% of Copeland Capital Management's portfolio in Q2 2026, its #225 holding.
Copeland Capital Management first reported a position in Pfizer in Q2 2013 and has held it in 52 quarters since.
Copeland Capital Management's Pfizer position peaked at $350K in Q3 2018.
2,818 funds tracked by Wall St. Rank held Pfizer as of Q2 2026.

Based on Copeland Capital Management's 13F filing for Q2 2026, filed 4 Aug 2026.